Article Figures & Data
Figures
- FIGURE 1.
18F-FDG PET/CT scan. Initial staging showing intensely 18F-FDG–avid right-upper-lobe mass with additional 18F-FDG–avid mediastinal lymph nodes. From right to left maximum-intensity-projection PET, coronal PET, coronal PET/CT, and axial PET/CT images.
- FIGURE 2.
18F-fluoride PET/CT scan. Diffuse bony metastasis with intense 18F-fluoride uptake is seen. From right to left maximum-intensity-projection PET, coronal PET, sagittal PET/CT, and coronal PET/CT images.
- FIGURE 3.
68Ga-DOTATATE PET/CT scan. Diffuse bony metastasis is noted; uptake of 68Ga-DOTATATE is less prominent than that of 18F-fluoride in Figure 2. Liver and pleural involvement seen on subsequent 18F-FDG scan 1 wk later is not clearly appreciated with 68Ga-DOTATATE. From right to left maximum-intensity-projection PET, coronal PET, sagittal PET/CT, and coronal PET/CT images.
- FIGURE 4.
18F-FDG PET scan showing diffuse bony lesions but also detecting pleural and very minimal subtle liver disease not visualized on 68Ga-DOTATATE scan. From right to left maximum-intensity-projection PET, coronal PET, coronal PET/CT, and sagittal PET/CT images.
- FIGURE 5.
(A) Initial staging 18F-FDG PET/CT scan. (B) Seven months later, 18F-fluoride PET/CT scan shows diffuse bony metastasis. (C) Additional 68Ga-DOTATATE PET/CT scan 2 wk later shows bony lesions less prominently than on 18F-fluoride scan, somewhat similar to follow-up 18F-FDG PET/CT scan. (D) Follow-up 18F-FDG PET/CT scan 1 wk later shows bony lesions and pleural and liver disease.
